Natco Pharma has filed a patent challenge against Novartis and Astex in the Delhi High Court, alleging that the two companies unlawfully secured dual patents for the same breast cancer drug invention—the Ribociclib molecule. This is a standard regulatory dispute within pharmaceutical patent litigation, which is common in emerging markets where patent scope interpretations differ from developed markets.
The core allegation centers on patent evergreening—a practice where companies extend exclusivity periods by obtaining multiple patent grants for incremental variations of the same molecule. If Natco succeeds, it could undermine Novartis's exclusivity on Ribociclib in India, potentially allowing Natco to launch a generic or biosimilar version earlier than currently permitted. The court will first assess the petition's maintainability before substantive arguments commence.
For Novartis, a loss in this case creates precedent risk for other patent portfolios in India's high-growth pharmaceutical market. For Natco, a successful challenge expands market access for oncology products. However, the timeline remains extended—further hearings are scheduled for September 16, meaning resolution is months or years away.
Sector implication: This dispute is localized to India's patent jurisprudence and poses modest systemic risk to global pharma IP protection. The broader Health Care sector sentiment remains neutral, though emerging-market generic manufacturers may view this as a favorable precedent for challenging multinational patent positions in high-growth jurisdictions.